These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21454970)

  • 1. Cefepime resistance and associated risk factors among Escherichia coli strains isolated from clinical specimens.
    Mansouri M; Ramazanzadeh R; Norabadi P
    Chemotherapy; 2011; 57(2):134-7. PubMed ID: 21454970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection].
    Chen YH; Yao WZ; Wu R; Zhou QT; Liu ZY; Zhang XW
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):815-9. PubMed ID: 19080534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
    Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
    J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors.
    Ozgunes I; Erben N; Kiremitci A; Kartal ED; Durmaz G; Colak H; Usluer G; Colak E
    Saudi Med J; 2006 May; 27(5):608-12. PubMed ID: 16680246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
    Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
    J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae acquisition in a neonatal intensive care unit.
    Shakil S; Ali SZ; Akram M; Ali SM; Khan AU
    J Trop Pediatr; 2010 Apr; 56(2):90-6. PubMed ID: 19608665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.
    Mammeri H; Nazic H; Naas T; Poirel L; Léotard S; Nordmann P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4050-3. PubMed ID: 15388478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiresistant Escherichia coli from elderly patients].
    Slucky-Shraga I; Wolk M; Volis S; Vulikh I; Sompolinsky D
    Harefuah; 2000 Jul; 139(1-2):25-9, 79. PubMed ID: 10979448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.
    Sotto A; De Boever CM; Fabbro-Peray P; Gouby A; Sirot D; Jourdan J
    J Clin Microbiol; 2001 Feb; 39(2):438-44. PubMed ID: 11158087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.